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In this issue of Blood, Ouedraogo et al have investigated the role of HIV and Epstein-Barr virus (EBV) replication in the persistence of monoclonal gammopathy. 1 It has been known for some time that patients with HIV infection have an increased incidence of monoclonal gammopathy and plasma cell dyscrasias. 2, 3 The exact mechanism of monoclonal gammopathy in patients with HIV infection is unknown, but in many patients the monoclonal gammopathy and other B-cell abnormalities can be reversed with antiretroviral therapy. However, a proportion of patients will have persistent monoclonal gammopathy.
O uedraogo et al identified 21 patients with
HIV infection in whom a monoclonal protein (M-protein) was identified by serum electrophoresis and immunofixation. The M-protein was unquantifiable (ie, had a very low concentration) in the majority (15/21; 71%) of HIV patients, with a median of 0.31 g/dL. The age of patients with monoclonal gammopathy was lower in this small cohort of HIV-infected patients (range, 20-58 y) than in previous reports based on the general population (typically detected above the age of 50). 4 All HIVinfected patients were treated with antiretroviral therapy, and the monoclonal gammopathy resolved in 12 of 21 (58%) patients; the remaining 9 (42%) patients had a persistent monoclonal gammopathy after at least 5 years of antiretroviral therapy. These 9 patients also had higher serum immunoglobulin levels as well as circulating plasmablasts and plasma cells in peripheral blood. Interestingly, 6 of 9 (66%) and 1 of 12 (8%) patients with persistent and transient monoclonal gammopathy had quantifiable EBV DNA in plasma, respectively. In addition, the EBV DNA B-cell reservoir and the EBV DNA produced by infected B cells in culture were significantly higher in patients with persistent monoclonal gammopathy when compared with patients with transient gammopathy and normal controls. These observations based on small numbers are supportive of a biological role for EBV in persistent monoclonal gammopathy in HIV infection.
Furthermore, these results are analogous to the monoclonal gammopathy seen in patients with solid organ transplantation. 5, 6 The increased risk of posttransplant persistent monoclonal gammopathy has been associated with increased frequency of EBV-infected cells and EBV reactivation. 7, 8 Indeed, recent population-based data provide evidence to support a role for EBV infection in the pathogenesis of plasma cell dyscrasias in solid organ transplant recipients. 9 In addition, previous studies have found serumfree light-chain abnormalities (a marker of polyclonal B-cell activation) to be associated with HIV infection and lymphoproliferative malignancies. 10 Taken G uidance from expert panels on how to treat medical conditions abound, and it is easy to be jaded into thinking they represent no more than a "World According To Us" view of managing disease. But the ELN Expert Panel stepped up to the task of making rigorous recommendations. How did they do it? They started by identifying experts on the basis of established criteria, such as those of the National Institutes of Health Consensus Development Program 2 and not on the basis of proximity to their offices. Check. They then systematically reviewed the literature for all articles guiding practice, both full manuscripts and abstracts at major conferences. Check minus, because the ELN used only English-language articles, and it did not disclose how many were . This is reflected as persistent monoclonal gammopathy, detectable in the peripheral blood. Alternative explanations may be that the EBV-infected memory B cells may act as stimulators of plasma cells or that the observed increased numbers of EBV-infected memory B cells and increased numbers of plasma cells may be independent of one another. Future functional studies are needed to better characterize mechanisms leading to persistent monoclonal gammopathy in HIV-infected patients. Professional illustration by Debra T. Dartez.
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